Sun. Apr 12th, 2026

TNXP Awaits Data In Q2, LLY Uncovers Ixekizumab’s Potential, High Five For MNOV

ByRTT - Top Story

Mar 7, 2016

MediciNova Inc.’s (MNOV) phase II trial results of MN-166 (ibudilast) in opioid dependence have been encouraging.

By RTT - Top Story

Related Post

Unlock the Profits of the Forex Market with Winning Strategies

May 28, 2023 admin

Master the Art of Forex Trading with These Proven Strategies

May 28, 2023 admin

Take Control of Your Investments with Strategic Forex Trading Strategies

May 28, 2023 admin

You missed

Europe’s Stablecoin Surge: Banks & Corporates Pave the Way for Institutional Adoption

Apr 12, 2026 admin

Hyperliquid ETF Approval Looms? Bitwise Filing Signals Major Shift for Crypto Investors

Apr 12, 2026 admin

Navigating the Regulatory Storm: US Crypto Market Structure Bill Reaches Critical Juncture

Apr 12, 2026 admin

The Great Blockchain Exodus: How Market Makers Are Shielding Their Alpha from Public View

Apr 12, 2026 admin